| __timestamp | ACADIA Pharmaceuticals Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 54170000 |
| Thursday, January 1, 2015 | 90804000 | 65378000 |
| Friday, January 1, 2016 | 186456000 | 52263000 |
| Sunday, January 1, 2017 | 255062000 | 35072000 |
| Monday, January 1, 2018 | 265758000 | 27415000 |
| Tuesday, January 1, 2019 | 325638000 | 36983000 |
| Wednesday, January 1, 2020 | 388661000 | 50918000 |
| Friday, January 1, 2021 | 396028000 | 63586000 |
| Saturday, January 1, 2022 | 369090000 | 57967000 |
| Sunday, January 1, 2023 | 402466000 | 53107000 |
| Monday, January 1, 2024 | 23626000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, ACADIA Pharmaceuticals Inc. and Mesoblast Limited have shown contrasting trends in their SG&A costs. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. In contrast, Mesoblast's expenses remained relatively stable, with a modest increase of about 2% over the same period. This stark difference highlights ACADIA's aggressive expansion strategy, while Mesoblast appears to focus on cost containment. Notably, ACADIA's expenses in 2023 were nearly seven times higher than Mesoblast's, raising questions about the sustainability of such growth. As we look to the future, the missing data for 2024 suggests uncertainty, but the trends so far provide valuable insights into each company's financial strategies.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Mesoblast Limited
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Who Optimizes SG&A Costs Better? GSK plc or Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared